In knee replacement patients, teriparatide did not change maximal total point motion versus untreated control from 12 to 24 months.
In plain wordsIn knee replacement patients, teriparatide did not change implant movement versus untreated control.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeMaximal total point motion
- Study
n = 50
- Comparator
- Untreated control
- Analysis
- Primary
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 20 μg daily · 2 monthsAs given in this study (human).
Measurements
- Median maximal total point motion
- 0.14 mm
- teriparatide
- 10th to 90th percentile
- 0.08 to 0.24 mm
- teriparatide
- Median maximal total point motion
- 0.13 mm
- control
- 10th to 90th percentile
- 0.09 to 0.21 mm
- control
- 95% CI for difference between group means
- −0.03 to 0.04 mm
- teriparatide versus control
Source sentences
Results - Median maximal total point motion from 12 to 24 months was similar in the 2 groups (teriparatide: 0.14 mm, 10% and 90% percentiles: 0.08 and 0.24; control: 0.13 mm, 10% and 90% percentiles: 0.09 and 0.21).
2 context sentences(design, population, supporting numbers)
The 95% confidence interval for the difference between group means was -0.03 to 0.04 mm, indicating that no difference occurred.
Patients and methods - In a randomized controlled trial with blind evaluation, 50 patients with osteoarthritis of the knee were allocated to a teriparatide treatment group (Forsteo, 20 μg daily for 2 months postoperatively) or to an untreated control group.